NCT00192517已完成2 期
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 20
- 主要终点
- Percentage of subjects achieving at least a 50% or 75% improvement of PASI
研究概览
简要总结
The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Plaque psoriasis involving at least 10% of body surface area (Appendix A)
- •PASI score greater than 12
- •Age 18 through 65 years at the time of the first dose of study drug
- •Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of study drug and must agree to continue using such precautions for 60 days after the final dose of study drug
- •Prior to randomization (must be within 21 days of the first administration of the study drug), all of the following: WBC less than or equal to 3,800/mm3; hematocrit above 32%, platelet count less than or equal to 140,000/mm3; AST, ALT, BUN, or creatinine<1.5 x ULN; and stool negative for occult blood
- •Currently receiving no therapy for psoriasis except emollients
- •Written informed consent obtained from the patient
- •Ability to complete follow-up period of 167 days as required by the protocol
排除标准
- •Pustular, guttate, or erythrodermic psoriasis as the predominant disease type
- •Evidence of active hepatitis A, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, such as positive HBsAg or positive anti-hepatitis C antibody
- •Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first dose of study drug, and urine pregnancy test must be negative on Study Day 0 before study entry)
- •History of cancer (except excision of basal cell carcinoma)
- •Evidence of significant active infection, such as fever less than or greater to 38.0°C (100.5°F), or chronic systemic infection
- •Known or suspected infection with human immunodeficiency virus (HIV) or other evidence of clinically significant immune deficiencies
- •Diagnosis of psoriatic arthritis or rheumatoid arthritis requiring active treatment
- •History of hematuria due to chronic cystitis, recurrent kidney stones, or nephritis, history of CVA, poorly controlled hypertension, angina, stable abdominal aneurysm, recent superficial phlebitis, or recent myocardial infarction (within past 1 year without definitive corrective surgery such as coronary bypass graft or angioplasty)
- •Receipt of systemic therapy for psoriasis or immunosuppressive medication in the past 4 weeks, including systemic retinoids, systemic steroids (oral, IM, or IV), cyclosporine A,methotrexate, azathioprine, anti-TNF agents, anti-T-cell agents, phototherapy (PUVA, UVB,tanning bed use), coal tar treatment (Goeckerman or modified Goeckerman regimen), tacrolimus, or mycophenolate
- •Use of topical therapy for psoriasis in the past 2 weeks, such as steroid containing creams, Vitamin D analog creams and coal tar shampoos
- •Receipt of any investigational drug therapy within 4 weeks before the first dose of study drug in this protocol (use of licensed agents for indications not listed in the package insert is permitted)
- •Current or planned participation in a research protocol in which an investigational agent or therapy may be administered
- •History of allergic disease or reactions likely to be exacerbated by any component of MEDI-522
- •Nursing mother
- •Evidence of acute illness
- •Clinical manifestations of significant end organ dysfunction or failure that may compromise the safety of the patient in the study
- •History of gastrointestinal bleeding (i.e., stool positive for occult blood or overt bleeding) within the previous 6 months
- •Known bleeding disorder or significant risk of clinically important abnormal bleeding due to anticoagulant therapy with warfarin or heparin
- •Insulin-dependent diabetes mellitus that is recent-onset or unstable
- •Elective surgery planned during the study period through Study Day 167
研究组 & 干预措施
1
Active Comparator
MEDI-522
干预措施: MEDI-522 (Drug)
2
Placebo Comparator
Placebo
干预措施: Placebo (Other)
结局指标
主要结局
Percentage of subjects achieving at least a 50% or 75% improvement of PASI
时间窗: PASI score at Study Days 28, 56, 77, 91, 107, 137, and 167.
次要结局
- Incidence of adverse events and serious adverse events(through Study Day 167)
研究者
研究点 (20)
Loading locations...
相似试验
尚未招募
2 期
A study of the safety and efficacy of 7 days treatment with BIT225 in patients with COVID-19, compared to placebo, including measurement of antiviral activity, clinical recovery and immune biomarkers.COVID-19Infection - Other infectious diseasesACTRN12623000035628Biotron Limited60
进行中（未招募）
1 期
A Phase 2 Study of RSLV-132 in Subjects with Sjogren’s SyndromePrimary Sjogrens SyndromeEUCTR2016-001586-87-GBResolve Therapeutics, LLC28
已完成
不适用
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Patients With Type 2 Diabetes MellitusPER-013-10Astellas Pharma Global Development, Inc. (APGD),
已完成
2 期
A study to evaluate the effect of ASP 1941 in adult patients with type 2 diabetes mellitusCTRI/2010/091/000343Astellas Pharma Inc378
进行中（未招募）
不适用
A Phase 2 study to test how effective MEDI8968 is in treating subjects with chronic bronchitis, emphysema, or both, in which airflow to the lungs is restricted.Chronic Obstructive Pulmonary DiseaseMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-002563-23-LTMedImmune Limited300